-
1
-
-
0034473683
-
Epidemiology of rheumatic diseases
-
Sangha O. Epidemiology of rheumatic diseases. Rheumatology 2000;39 Suppl 2:3-12.
-
(2000)
Rheumatology
, vol.39
, Issue.SUPPL. 2
, pp. 3-12
-
-
Sangha, O.1
-
2
-
-
0029091107
-
Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)
-
van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22:1792-6.
-
(1995)
J Rheumatol
, vol.22
, pp. 1792-1796
-
-
Van Der Heijde, D.M.1
Van Leeuwen, M.A.2
Van Riel, P.L.3
Van De Putte, L.B.4
-
3
-
-
0037629038
-
Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis
-
Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003;62:611-6.
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 611-616
-
-
Lindqvist, E.1
Jonsson, K.2
Saxne, T.3
Eberhardt, K.4
-
4
-
-
33749319744
-
Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
-
Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2784-2792
-
-
Aletaha, D.1
Smolen, J.2
Ward, M.M.3
-
5
-
-
84960559189
-
Joint erosions and patients with early rheumatoid arthritis
-
van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74-8.
-
(1995)
Br J Rheumatol
, vol.34
, Issue.SUPPL. 2
, pp. 74-78
-
-
Van Der Heijde, D.M.1
-
6
-
-
0036210080
-
Early referral recommendation for newly diagnosed rheumatoid arthritis: Evidence based development of a clinical guide
-
Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 290-297
-
-
Emery, P.1
Breedveld, F.C.2
Dougados, M.3
Kalden, J.R.4
Schiff, M.H.5
Smolen, J.S.6
-
7
-
-
77950307115
-
Treating rheumatoid arthritis to target: Recommendations of an international task force
-
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 631-637
-
-
Smolen, J.S.1
Aletaha, D.2
Bijlsma, J.W.3
Breedveld, F.C.4
Boumpas, D.5
Burmester, G.6
-
8
-
-
61549091538
-
Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis
-
Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol 2009;28:413-9.
-
(2009)
Clin Rheumatol
, vol.28
, pp. 413-419
-
-
Jamal, S.1
Patra, K.2
Keystone, E.C.3
-
9
-
-
78149278597
-
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER
-
van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
-
(2010)
J Rheumatol
, vol.37
, pp. 2237-2246
-
-
Van Der Heijde, D.1
Breedveld, F.C.2
Kavanaugh, A.3
Keystone, E.C.4
Landewe, R.5
Patra, K.6
-
10
-
-
77953694972
-
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA
-
Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 976-986
-
-
Nam, J.L.1
Winthrop, K.L.2
Van Vollenhoven, R.F.3
Pavelka, K.4
Valesini, G.5
Hensor, E.M.6
-
11
-
-
84859832981
-
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
-
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
-
(2012)
Arthritis Care Res
, vol.64
, pp. 625-639
-
-
Singh, J.A.1
Furst, D.E.2
Bharat, A.3
Curtis, J.R.4
Kavanaugh, A.F.5
Kremer, J.M.6
-
12
-
-
77953696525
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
-
Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 964-975
-
-
Smolen, J.S.1
Landewe, R.2
Breedveld, F.C.3
Dougados, M.4
Emery, P.5
Gaujoux-Viala, C.6
-
13
-
-
2342658406
-
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial
-
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 1400-1411
-
-
Keystone, E.C.1
Kavanaugh, A.F.2
Sharp, J.T.3
Tannenbaum, H.4
Hua, Y.5
Teoh, L.S.6
-
14
-
-
0034735842
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group
-
Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
-
(2000)
N Engl J Med
, vol.343
, pp. 1594-1602
-
-
Lipsky, P.E.1
Van Der Heijde, D.M.2
St. Clair, E.W.3
Furst, D.E.4
Breedveld, F.C.5
Kalden, J.R.6
-
15
-
-
10744223002
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
-
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
-
(2004)
Lancet
, vol.363
, pp. 675-681
-
-
Klareskog, L.1
Van Der Heijde, D.2
De Jager, J.P.3
Gough, A.4
Kalden, J.5
Malaise, M.6
-
16
-
-
31044442965
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 26-37
-
-
Breedveld, F.C.1
Weisman, M.H.2
Kavanaugh, A.F.3
Cohen, S.B.4
Pavelka, K.5
Van Vollenhoven, R.6
-
17
-
-
0029044362
-
American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis
-
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
-
(1995)
Arthritis Rheum
, vol.38
, pp. 727-735
-
-
Felson, D.T.1
Anderson, J.J.2
Boers, M.3
Bombardier, C.4
Furst, D.5
Goldsmith, C.6
-
18
-
-
0023945481
-
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
-
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
-
(1988)
Arthritis Rheum
, vol.31
, pp. 315-324
-
-
Arnett, F.C.1
Edworthy, S.M.2
Bloch, D.A.3
McShane, D.J.4
Fries, J.F.5
Cooper, N.S.6
-
19
-
-
84866104476
-
Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: Results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
-
Smolen JS, Kay J, Landewe RB, Matteson EL, Gaylis N, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012;71:1671-9.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1671-1679
-
-
Smolen, J.S.1
Kay, J.2
Landewe, R.B.3
Matteson, E.L.4
Gaylis, N.5
Wollenhaupt, J.6
-
20
-
-
79960141758
-
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis
-
Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res 2011; 63:373-82.
-
(2011)
Arthritis Care Res
, vol.63
, pp. 373-382
-
-
Weinblatt, M.E.1
Bathon, J.M.2
Kremer, J.M.3
Fleischmann, R.M.4
Schiff, M.H.5
Martin, R.W.6
-
21
-
-
84883371895
-
Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: Final 10-year data in longstanding rheumatoid arthritis
-
Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, et al. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013;40:1487-97.
-
(2013)
J Rheumatol
, vol.40
, pp. 1487-1497
-
-
Keystone, E.C.1
Van Der Heijde, D.2
Kavanaugh, A.3
Kupper, H.4
Liu, S.5
Guerette, B.6
-
22
-
-
84863871272
-
Assessing the safety of biologic agents in patients with rheumatoid arthritis
-
Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 2012;51 Suppl 5:v38-47.
-
(2012)
Rheumatology
, vol.51
, Issue.SUPPL. 5
-
-
Rubbert-Roth, A.1
-
23
-
-
21744457266
-
Adalimumab: A review of side effects
-
Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4:637-41.
-
(2005)
Expert Opin Drug Saf
, vol.4
, pp. 637-641
-
-
Scheinfeld, N.1
-
24
-
-
19644364586
-
The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel
-
Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
-
(2005)
Semin Arthritis Rheum
, vol.34
, pp. 819-836
-
-
Hochberg, M.C.1
Lebwohl, M.G.2
Plevy, S.E.3
Hobbs, K.F.4
Yocum, D.E.5
-
25
-
-
84874445437
-
Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
-
Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 517-524
-
-
Burmester, G.R.1
Panaccione, R.2
Gordon, K.B.3
McIlraith, M.J.4
Lacerda, A.P.5
-
26
-
-
78751703180
-
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: Exploratory analyses from the BeSt study
-
Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, van Groenendael JH, Han KH, Kerstens PJ, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-9.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 315-319
-
-
Klarenbeek, N.B.1
Van Der Kooij, S.M.2
Guler-Yuksel, M.3
Van Groenendael, J.H.4
Han, K.H.5
Kerstens, P.J.6
-
27
-
-
48149100741
-
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial
-
Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
-
(2008)
Lancet
, vol.372
, pp. 375-382
-
-
Emery, P.1
Breedveld, F.C.2
Hall, S.3
Durez, P.4
Chang, D.J.5
Robertson, D.6
|